Clinical Trials Logo

Clinical Trial Summary

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by social impairment, repetitive behaviors, and narrow interests. With advancements in diagnostic techniques, the prevalence of ASD has been increasing annually. However, due to its complex and diverse etiology, there is no definitive consensus on the pathogenic mechanism of ASD. Numerous studies indicate that genetics, environment, and other factors play crucial roles in the onset of ASD. Vitamin A (VA) exerts its effects in the body through its active metabolite, retinoic acid (RA), which regulates the transcriptional activity and expression of downstream genes by binding to retinoic acid receptors (RARs/RXRs). Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is an immunoglobulin-like receptor present on microglial cells, with functions including inhibiting the production of inflammatory factors and engulfing apoptotic neurons. Recent foreign studies show a significant decrease in TREM2 levels in the brain tissue of ASD patients. However, there is limited research on the relationship between TREM2 and ASD. In our previous animal experiments, we observed a reduction in TREM2 in the prefrontal cortex of the brain in ASD model rats. Administering overexpressed TREM2 improved autism-like behavior in ASD model rats, and supplementing RA upregulated the expression of RA-RARĪ± and TREM2, modulated microglial cell activation, and improved autism-like behavior in rats. Therefore, we believe that the RA/RARĪ± pathway regulates the TREM-2 signaling pathway, mediating changes in microglial cells, and TREM2 may be involved in the pathogenesis of ASD. Soluble TREM2 (sTREM2) is formed by the extracellular domain shedding of TREM2 under the action of ADAM protease. Research indicates that the expression of sTREM2 can be detected in cerebrospinal fluid and plasma. However, the connection between VA, sTREM2 levels, and the behavioral and developmental levels of children with ASD remains unclear and requires further clinical research to validate. This will help deepen our understanding of TREM2 expression in ASD, its potential biological functions, and the role of RA.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06188429
Study type Observational
Source Children's Hospital of Chongqing Medical University
Contact Wei Hua
Phone 18580476890
Email weihua6280@163.com
Status Recruiting
Phase
Start date November 20, 2023
Completion date October 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02847182 - Cord Blood Infusion for Children With Autism Spectrum Disorder Phase 2
Completed NCT02708290 - Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Completed NCT04771338 - Examining the Effects of a Job Entry Intervention N/A
Completed NCT04178421 - Computerized Eye-tracking Attention Training for Children With Special Needs N/A
Completed NCT02985749 - A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder Phase 3
Recruiting NCT06012903 - Lower Urinary Tract Symptoms and School Functioning in Children
Not yet recruiting NCT04418921 - Improving Self-regulation in Children With Neurodevelopmental Disorders: N/A
Completed NCT01931033 - An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders N/A
Recruiting NCT04899544 - Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism N/A
Recruiting NCT06155214 - Developmental Regression-related Disease Research and Achievement Transformation Innovation Team
Active, not recruiting NCT01932515 - Diagnostic Instruments for Autism in Deaf Children Study N/A
Completed NCT06209463 - Posture, Hand Functions and Sensory Processing Skills on Nutrition
Recruiting NCT06155201 - Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders N/A
Recruiting NCT03502239 - Cognitive Rehabilitation (Mega Team) and Its Effects on Emotional and Behavioral Regulation in ADHD, ASD, and CHD N/A
Withdrawn NCT03829878 - Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) Phase 2
Recruiting NCT02461446 - Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
Active, not recruiting NCT03900923 - Cannabidiol for ASD Open Trial Phase 2
Recruiting NCT06339359 - A Pilot Study to Develop a Behavior-based Screening Protocol for Early Diagnosis of Autism Spectrum Disorders
Completed NCT03099239 - hCT-MSCs for Children With Autism Spectrum Disorder (ASD) Phase 1
Terminated NCT05733390 - A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder Phase 2